JPWO2020016318A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020016318A5 JPWO2020016318A5 JP2021502435A JP2021502435A JPWO2020016318A5 JP WO2020016318 A5 JPWO2020016318 A5 JP WO2020016318A5 JP 2021502435 A JP2021502435 A JP 2021502435A JP 2021502435 A JP2021502435 A JP 2021502435A JP WO2020016318 A5 JPWO2020016318 A5 JP WO2020016318A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- degrading enzyme
- gene therapy
- aav
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024051529A JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305971 | 2018-07-17 | ||
| EP18305971.6 | 2018-07-17 | ||
| US201862768731P | 2018-11-16 | 2018-11-16 | |
| US62/768,731 | 2018-11-16 | ||
| PCT/EP2019/069280 WO2020016318A1 (en) | 2018-07-17 | 2019-07-17 | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024051529A Division JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529821A JP2021529821A (ja) | 2021-11-04 |
| JP2021529821A5 JP2021529821A5 (https=) | 2022-05-13 |
| JPWO2020016318A5 true JPWO2020016318A5 (https=) | 2022-05-13 |
Family
ID=67303476
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502435A Pending JP2021529821A (ja) | 2018-07-17 | 2019-07-17 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
| JP2024051529A Pending JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024051529A Pending JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20210228738A1 (https=) |
| EP (2) | EP4154904A1 (https=) |
| JP (2) | JP2021529821A (https=) |
| KR (1) | KR20210042308A (https=) |
| CN (2) | CN112689515A (https=) |
| AU (2) | AU2019306121B2 (https=) |
| BR (1) | BR112021000807A8 (https=) |
| CA (1) | CA3106368A1 (https=) |
| CL (1) | CL2021000112A1 (https=) |
| CO (1) | CO2021000326A2 (https=) |
| DK (1) | DK3768304T3 (https=) |
| ES (1) | ES2935970T3 (https=) |
| FI (1) | FI3768304T3 (https=) |
| HR (1) | HRP20221542T1 (https=) |
| HU (1) | HUE060720T2 (https=) |
| IL (1) | IL280099A (https=) |
| LT (1) | LT3768304T (https=) |
| MX (1) | MX2021000580A (https=) |
| PE (1) | PE20211859A1 (https=) |
| PH (1) | PH12021550115A1 (https=) |
| PL (1) | PL3768304T3 (https=) |
| RS (1) | RS63878B1 (https=) |
| SG (1) | SG11202100306VA (https=) |
| SI (1) | SI3768304T1 (https=) |
| SM (1) | SMT202300005T1 (https=) |
| UA (1) | UA130604C2 (https=) |
| WO (1) | WO2020016318A1 (https=) |
| ZA (1) | ZA202100202B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4219547A3 (en) | 2008-09-15 | 2023-10-18 | uniQure biopharma B.V. | Factor ix polypeptide mutant, its uses and a method for its production |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| CN112543766A (zh) | 2018-04-03 | 2021-03-23 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| US20210363191A1 (en) | 2018-04-03 | 2021-11-25 | Stridebio, Inc. | Antibody-evading virus vectors |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| US20200165608A1 (en) * | 2018-11-23 | 2020-05-28 | Florida State University Research Foundation, Inc. | Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions |
| AU2020215682B2 (en) * | 2019-01-28 | 2025-12-18 | Duke University | Compositions and methods for evading humoral immunity |
| CN114732822B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| BR112021018776A2 (pt) | 2019-03-21 | 2021-11-30 | Stridebio Inc | Vetores de vírus adenoassociado recombinante |
| AR118928A1 (es) * | 2019-05-14 | 2021-11-10 | Biomarin Pharm Inc | Métodos de redosificación de vectores de terapia génica |
| US12544437B2 (en) | 2019-10-04 | 2026-02-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant AAV |
| KR20220083714A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터 |
| US11180540B2 (en) | 2019-12-06 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| KR20220133969A (ko) | 2020-01-28 | 2022-10-05 | 프리라인 테라퓨틱스 리미티드 | 바이러스 벡터에 대한 중화 항체 역가를 결정하기 위한 개선된 분석법 |
| MX2022009982A (es) | 2020-02-14 | 2022-09-12 | Ultragenyx Pharmaceutical Inc | Terapia genica para el tratamiento de transtorno por deficiencia de cdkl5. |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| CN111621506B (zh) * | 2020-05-09 | 2021-07-30 | 华中农业大学 | 牛支原体分泌蛋白MbovP0145及其应用 |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| EP4162951A4 (en) * | 2020-06-05 | 2024-07-10 | Shanghai Bao Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND ASSOCIATED APPLICATION |
| JP2023532219A (ja) * | 2020-06-18 | 2023-07-27 | 上海宝済薬業有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの突然変異体 |
| RU2020122141A (ru) * | 2020-07-03 | 2022-01-04 | Максим Петрович Никитин | Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови |
| WO2022026632A2 (en) * | 2020-07-29 | 2022-02-03 | University Of Florida Research Foundation, Incorporated | Improved aav-mediated x-linked retinoschisis therapies |
| EP4200408A1 (en) | 2020-08-19 | 2023-06-28 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of rett syndrome |
| AU2021350732A1 (en) * | 2020-09-28 | 2023-05-11 | Scout Bio, Inc. | Composition and uses thereof |
| AU2021358957A1 (en) | 2020-10-07 | 2023-06-08 | AskBio Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 |
| EP4304662A4 (en) * | 2021-03-08 | 2025-06-18 | The Regents of the University of California | Lentivirus protection via fc overexpression |
| WO2022192193A1 (en) * | 2021-03-09 | 2022-09-15 | The Board Of Regents Of The University Of Texas System | Methods and compositions for mutagenesis screening in mammalian cells |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| WO2023280175A1 (en) * | 2021-07-06 | 2023-01-12 | National Institute Of Biological Sciences, Beijing | Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis |
| WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| EP4349365A1 (en) * | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115558021B (zh) * | 2022-12-01 | 2023-03-17 | 山东大学 | 一种转录因子、重组细胞及其在制备肿瘤治疗药物的应用 |
| CN116425873B (zh) * | 2023-06-02 | 2023-09-05 | 苏州百道医疗科技有限公司 | 一种抗ck6重组兔单克隆抗体及其应用 |
| CN117126270B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种2型人博卡病毒型别特异性抗体及其应用 |
| CN118217443B (zh) * | 2024-01-15 | 2026-04-03 | 国科温州研究院(温州生物材料与工程研究所) | 一种人发角蛋白止血海绵及其制备方法与应用 |
| WO2025155923A1 (en) | 2024-01-17 | 2025-07-24 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor |
| WO2025217174A1 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv |
| WO2025217163A2 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Novel aav capsids binding to human cd59 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| WO2026041758A1 (en) * | 2024-08-22 | 2026-02-26 | Genethon | Modified aav capsid with enhanced transduction efficiency |
| GB202414654D0 (en) | 2024-10-04 | 2024-11-20 | Hansa Biopharma AB | Regimen for vector-based therapies |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US414A (en) | 1837-09-28 | Moetise-latch foe | ||
| US941A (en) | 1838-09-22 | Machine for sawing shingles and staves | ||
| US5173A (en) | 1847-06-26 | Machinery for | ||
| US5139A (en) | 1847-06-05 | Cajsfkles | ||
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| AU7676894A (en) | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US6579520B2 (en) | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| JP5427409B2 (ja) * | 2005-06-09 | 2014-02-26 | ハンサ メディカル アクチボラゲット | 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用 |
| EP3192788A1 (en) | 2006-10-03 | 2017-07-19 | Arbutus Biopharma Corporation | Lipid containing formulations |
| US7649243B2 (en) | 2006-11-06 | 2010-01-19 | International Business Machines Corporation | Semiconductor structures incorporating multiple crystallographic planes and methods for fabrication thereof |
| GB0624874D0 (en) | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| EP2219587A4 (en) | 2007-11-14 | 2012-11-21 | Univ California | STEROL-MODIFIED AMPHIPHILE LIPIDES |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| WO2010054384A1 (en) | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Lipids and compositions for the delivery of therapeutics |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
| WO2011141705A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| GB201103780D0 (en) | 2011-03-04 | 2011-04-20 | Hansa Medical Ab | Treatment for ige-mediated disease |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) * | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| SG11201405157PA (en) | 2012-02-24 | 2014-10-30 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
| AU2013249202B2 (en) | 2012-04-18 | 2018-08-09 | The Children's Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using AAV capsid variants |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP3605090A1 (en) | 2012-05-23 | 2020-02-05 | F. Hoffmann-La Roche AG | Selection method for therapeutic agents |
| HK1222673A1 (zh) | 2013-07-12 | 2017-07-07 | The Children's Hospital Of Philadelphia | Aav载体和用於抗aav(腺相关病毒)中和抗体的检测 |
| KR20240090694A (ko) | 2013-07-22 | 2024-06-21 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| AU2017207736A1 (en) * | 2016-01-11 | 2018-07-12 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| ES2877754T3 (es) | 2016-02-04 | 2021-11-17 | Genovis Ab | Nuevas proteasas estreptocócicas |
| WO2018093868A1 (en) | 2016-11-16 | 2018-05-24 | University Of Florida Research Foundation, Inc. | Immunoglobulin proteases, compositions, and uses thereof |
| WO2018109207A1 (en) | 2016-12-16 | 2018-06-21 | Uniqure Ip B.V. | Immunoadsorption |
| WO2018158397A1 (en) | 2017-03-02 | 2018-09-07 | Genethon | Method for removing anti-aav antibodies from a blood-derived composition |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
-
2017
- 2017-07-17 US US17/050,911 patent/US20210228738A1/en not_active Abandoned
-
2019
- 2019-07-17 PE PE2021000066A patent/PE20211859A1/es unknown
- 2019-07-17 SI SI201930426T patent/SI3768304T1/sl unknown
- 2019-07-17 PL PL19740384.3T patent/PL3768304T3/pl unknown
- 2019-07-17 EP EP22198839.7A patent/EP4154904A1/en active Pending
- 2019-07-17 HR HRP20221542TT patent/HRP20221542T1/hr unknown
- 2019-07-17 EP EP19740384.3A patent/EP3768304B1/en active Active
- 2019-07-17 KR KR1020217001502A patent/KR20210042308A/ko active Pending
- 2019-07-17 AU AU2019306121A patent/AU2019306121B2/en active Active
- 2019-07-17 WO PCT/EP2019/069280 patent/WO2020016318A1/en not_active Ceased
- 2019-07-17 SG SG11202100306VA patent/SG11202100306VA/en unknown
- 2019-07-17 ES ES19740384T patent/ES2935970T3/es active Active
- 2019-07-17 CN CN201980048115.9A patent/CN112689515A/zh active Pending
- 2019-07-17 LT LTEPPCT/EP2019/069280T patent/LT3768304T/lt unknown
- 2019-07-17 RS RS20221191A patent/RS63878B1/sr unknown
- 2019-07-17 HU HUE19740384A patent/HUE060720T2/hu unknown
- 2019-07-17 JP JP2021502435A patent/JP2021529821A/ja active Pending
- 2019-07-17 BR BR112021000807A patent/BR112021000807A8/pt unknown
- 2019-07-17 UA UAA202100146A patent/UA130604C2/uk unknown
- 2019-07-17 SM SM20230005T patent/SMT202300005T1/it unknown
- 2019-07-17 DK DK19740384.3T patent/DK3768304T3/da active
- 2019-07-17 CA CA3106368A patent/CA3106368A1/en active Pending
- 2019-07-17 FI FIEP19740384.3T patent/FI3768304T3/fi active
- 2019-07-17 CN CN202411396316.7A patent/CN119345338A/zh active Pending
- 2019-07-17 MX MX2021000580A patent/MX2021000580A/es unknown
-
2021
- 2021-01-11 IL IL280099A patent/IL280099A/en unknown
- 2021-01-12 ZA ZA2021/00202A patent/ZA202100202B/en unknown
- 2021-01-14 CL CL2021000112A patent/CL2021000112A1/es unknown
- 2021-01-15 PH PH12021550115A patent/PH12021550115A1/en unknown
- 2021-01-15 CO CONC2021/0000326A patent/CO2021000326A2/es unknown
- 2021-04-07 US US17/224,367 patent/US20210246469A1/en not_active Abandoned
-
2022
- 2022-07-12 US US17/862,622 patent/US20230142731A1/en active Pending
-
2024
- 2024-03-27 JP JP2024051529A patent/JP2024075765A/ja active Pending
-
2025
- 2025-08-13 AU AU2025217293A patent/AU2025217293A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020016318A5 (https=) | ||
| JP2021529821A5 (https=) | ||
| FI3768304T3 (fi) | Koostumuksia ja menetelmiä geeniterapiavektoreiden transduktion lisäämiseksi tai tehostamiseksi ja immunoglobuliinien poistamiseksi tai vähentämiseksi | |
| JP2020528734A5 (https=) | ||
| JP2003526377A (ja) | キメラキャプシドベクターの製造 | |
| JP2020520643A5 (https=) | ||
| WO2023060269A4 (en) | Recombinant adeno-associated viruses for targeted delivery | |
| JP2019524090A5 (https=) | ||
| US20240102050A1 (en) | Compositions and methods for treatment of neurological disorders | |
| JP7707081B2 (ja) | 網膜細胞を標的とした最適化された遺伝子治療 | |
| JP2025516136A5 (https=) | ||
| JPWO2022036220A5 (https=) | ||
| WO2002087594A1 (en) | Non-viral vesicle vector for cardiac specific gene delivery | |
| WO2024220719A1 (en) | Modified aav capsids for gene delivery | |
| JPWO2021014428A5 (https=) | ||
| JPWO2020214809A5 (https=) | ||
| JP2025515356A5 (https=) | ||
| EP4198047A1 (en) | Fukutin related protein gene transfer increase using modified itr sequences | |
| WO2024097439A1 (en) | Methods of treating human x-linked retinoschisis using gene therapy | |
| US20250325703A1 (en) | Composition for delivering gene to brain tissue and use thereof | |
| CA3233427A1 (en) | Slc13a5 gene therapy vectors and uses thereof | |
| JPWO2020237130A5 (https=) | ||
| US12480098B1 (en) | Adeno-associated virus variant | |
| EP4198048A1 (en) | Calpain-3 gene transfer increase using modified itr sequences | |
| WO2024216244A9 (en) | Targeting aav capsids, methods of manufacturing and using same |